Spero Therapeutics was established to discover and develop innovative therapies to address the critical unmet need for the treatment of multi-drug resistant infections.

Spero’s mission is to save lives and speed the recovery of patients with serious infections in the hospital and in the community.

Spero Therapeutics is committed to building a sustainable pipeline of programs with novel mechanisms to address current and future needs for antimicrobial therapy.

WHO IS SPERO?

- Founded in 2013 by Ankit Mahadevia, Michael Pucci and Milind Deshpande with seed money from Atlas Ventures and founding science from MGH/Harvard.
- Spero now has 20 employees, uses a hybrid model for research, has a broad and advancing pipeline and financial support in the form of $65M from a diverse group of partners.
- Spero maintains biology and pharmacology laboratories in Lexington, MA, USA and works closely with collaborators around the world to conduct research.
- Spero has a world-class research team and the support of world-leading advisors. In 2016 we will become a clinical-stage infectious disease company.

CONTACT

- Troy Lister: troy@sperotherapeutics.com

Spero maintains biology and pharmacology laboratories in Lexington, MA, USA and works closely with collaborators around the world to conduct research.

Spero has a world-class research team and the support of world-leading advisors. In 2016 we will become a clinical-stage infectious disease company.

Spero has a robust portfolio of novel compounds with activity against MDR Gram-positive and Gram-negative pathogens; our lead program will be in the clinic in 2H16.

Spero has an experienced team, world class advisors and the commitment and financial support to address the serious threat posed by antimicrobial resistance.

DHFR PROGRAM

- Dihydrofolate reductase (DHFR) is an essential enzyme involved in DNA synthesis.
- In collaboration with the University of Connecticut, Spero is in the process of optimizing lead molecules with IV/Oral exposure and activity against MDR Gram-positive and Gram-negative pathogens including trimethoprim resistant isolates.
- The program is structurally enabled and the lead series is not cross-resistant to known DHFR mutants (trimethoprim resistance).

SUMMARY

- Spero has a robust portfolio of novel compounds with activity against MDR Gram-negative pathogens; our lead program will be in the clinic in 2H16.
- Spero has an experienced team, world class advisors and the commitment and financial support to address the serious threat posed by antimicrobial resistance.

CONTACT

- Troy Lister: troy@sperotherapeutics.com